Ikervis (ciclosporin)
- Region
- 🇪🇺 EU
- Active substance
- ciclosporin
- Company
- Santen Oy
- Status
- Authorised
- Therapeutic area
- Corneal Diseases
- EU approval
- Thu 19 Mar 2015
- Application
- EMEA/H/C/002066
- ATC
- S01XA18
- Official record
- www.ema.europa.eu
Indication
Treatment of severe keratitis in adult patients with dry eye disease, which has not improved despite treatment with tear substitutes.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Verkazia Authorised · Santen Oy
- 🇪🇺 Vevizye Authorised · Laboratoires Théa
- 🇪🇺 Restaysis Application withdrawn · Allergan Pharmaceuticals International Limited
- 🇪🇺 Vekacia Application withdrawn · Novagali Pharma S.A.
Follow Ikervis
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.